In 51 infertile normoprolactinemic women, aged 19 to 44 years, with anovulatory menstrual cycles and with no endocrine disorders, who had never conceived after the currently employed drugs for
female sterility (
human chorionic gonadotropin,
human menopausal gonadotropin,
clomiphene,
cyclofenil, bromocryptine itself) a new therapeutic approach was tried:
cyclofenil and bromocryptine in association. Before the treatment, a standard
luteinizing hormone (
LH)-releasing hormone (
LHRH) test (100 micrograms intravenously) was performed for each woman to evaluate serum
gonadotropin and
prolactin response; furthermore, the urinary
estrogen excretion or the serum 17-beta-estradiol concentration had been evaluated in all women. The schedule of treatment was as follows:
cyclofenil, 600 mg/day, from the 5th to the 12th day of the cycle and bromocryptine, 2.5 mg/day, from the 5th to the 26th day. This scheme was employed for three successive trials at the most. Forty pregnancies (80%) were achieved with the associated
therapy, almost all (37) within the second treatment cycle. Thirty-one women delivered a vital baby, five are now pregnant, four aborted spontaneously. All seven women who had been unsuccessfully treated with bromocryptine alone, conceived after the associated regimen. In view of the excellent therapeutic results achieved in our hands, it is justified to consider our proposed scheme
cyclofenil-bromocryptine an effective
therapy for the management of infertile normo-prolactinemic women.